- Home
- LGVN
LGVN
Longeveron Inc.
as 02-21-2025 4:00pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Upcoming Earnings Alert:
Get ready for potential market movements as Longeveron Inc. LGVN prepares to release earnings report on 28 Feb 2025.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 25.2M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 161.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $6.40 | Next Earning Date: | 02-28-2025 |
| Revenue: | $1,852,000 | Revenue Growth: | 141.46% |
| Revenue Growth (this year): | 208.32% | Revenue Growth (next year): | 43.96% |
Stock Insider Trading Activity of Longeveron Inc. (LGVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baluch Khoso | LGVN | Director | Dec 2 '24 | Sell | $2.07 | 1,250 | $2,588.13 | 23,750 |
Latest Longeveron Inc. News
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
GlobeNewswire
3 days ago
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
MT Newswires
4 days ago
Longeveron Cellular Therapy Granted International Non-Proprietary Name
GlobeNewswire
4 days ago
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
GlobeNewswire
8 days ago
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
GlobeNewswire
2 months ago
Longeveron to Present at Biotech Showcase 2025
TipRanks
3 months ago
Longeveron initiated with a Buy at Roth MKM
GlobeNewswire
3 months ago
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
Compare LGVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.